Review the Lidocaine / Tetracaine / Phenylephrine source preparation, its listed specifications and the details your practice should confirm with the pharmacy.
For product identification and informed clinic review. No patient checkout is provided.
Optimal names Lidocaine / Tetracaine / Phenylephrine with 23% / 10% / 0.5% and a 60 mL package. Confirm component order, exact chemical forms, percentage basis, complete vehicle, dosage form and intended route.
Listed package: 60 mL. Confirm the complete formulation, ingredient identities, percentage basis, dosage form, labeling and current pharmacy requirements. Source specifications are not application or dosing instructions.
Explore source listing1 source entry. Open the pharmacy to review its listings and confirmation notes.
| Source preparation / review note | Listed amount / specification | Package |
|---|---|---|
| Lidocaine/Tetracaine/Phenylephrine 23%/10%/0.5%Dosage form and percentage basis require confirmation. Review the complete preparation independently. | 23% / 10% / 0.5% — source sequence | 60 mL |
Review the exact product with the responsible pharmacy before submitting an order.
Check the ingredient name and its complete specification.
Review product-specific evidence and regulatory information.
Confirm missing or conflicting fields with the pharmacy.
Any further action depends on the exact product and applicable requirements.
CoreLink does not prescribe or dispense. Reference listings are not offers to supply products.
The treating clinician determines suitability and prescribing. Review the exact preparation’s labeling and pharmacy information.
This three-ingredient source preparation is distinct from the two-ingredient Lidocaine / Tetracaine family and other combinations. Numerical fields are not an application amount or procedure protocol.
FDA’s NASEM summary describes limited evidence and important safety-data gaps for compounded topical pain creams. It does not validate this particular three-ingredient formula, establish its dosage form or supply a procedure protocol. FDA: NASEM compounded topical pain cream assessment
Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness or quality. For a commercially manufactured product, verify its exact identity and current labeling separately. FDA: compounded drug information
Sources checked October 20, 2026. This page provides product information, not diagnosis, treatment selection, dosing or administration instructions.
No. It lists ingredients, percentages and a package volume without explicitly naming a dosage form. Obtain the complete formulation, intended route, labeling and preparation-specific safety information.
No. A source entry does not establish approval, safety, effectiveness, current availability or eligibility. Review the exact preparation and current requirements with the responsible pharmacy.
No. Ingredient concentration, total content and package volume are separate specifications. This page gives no dosing, preparation or administration instructions.
No. Verify the exact product and its regulatory status. A compounded preparation is not FDA-approved, and a reference to an approved product does not establish equivalence.
A shared ingredient name or numerical value does not establish equivalence. Confirm the complete ingredient form, formulation, route and product labeling.
Ask for the exact ingredient identity, full formulation, strength units, dosage form, route, package, current labeling and applicable requirements. Resolve missing or conflicting information.
No. These pages provide reference information and no patient checkout. Patients should discuss treatment with their treating clinician.
Email info@corelinkpharm.com for platform questions. Contact the responsible pharmacy for preparation-specific information.
Contact CoreLink for account information. Ask the pharmacy about exact product specifications and eligibility.